Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Matsuda, M., & DeFronzo, R. A. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1462 · Cited by 5,621
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755
DeFronzo, R. A. (2009) · Diabetes · doi:10.2337/db09-9028 · Cited by 3,016
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial
Chiasson, J.-L., Josse, R. G., Gomis, R., Hanefeld, M., Karasik, A., & Laakso, M. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08905-5 · Cited by 2,543
Cited by
Prediabetes: a high-risk state for diabetes development
Tabák, A. G., Herder, C., Rathmann, W., Brunner, E. J., & Kivimäki, M. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60283-9 · Cited by 2,958
DeFronzo, R. A., Ferrannini, E., Groop, L., Henry, R. R., Herman, W. H., Holst, J. J., Hu, F. B., Kahn, C. R., Raz, I., Shulman, G. I., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.19 · Cited by 2,611
“serves on scientific advisory boards for Merck and Novartis and he has received research grant support from Gilead Pharmaceuticals; (12) D.”
BackgroundGarvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
Kahn, S. E., Cooper, M. E., & Del Prato, S. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62154-6 · Cited by 1,743
Type 2 diabetes across generations: from pathophysiology to prevention and management
Nolan, C. J., Damm, P., & Prentki, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60614-4 · Cited by 923
Type II diabetes mellitus: a review on recent drug based therapeutics.
Padhi, S., Nayak, A. K., & Behera, A. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110708 · Cited by 726
Prediabetes diagnosis and treatment: A review
Bansal, N. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i2.296 · Cited by 579
Mahfoud, F., Schlaich, M., Kindermann, I., Ukena, C., Cremers, B., Brandt, M. C., Hoppe, U. C., Vonend, O., Rump, L. C., Sobotka, P. A., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.991869 · Cited by 573
Tan, S. Y., Mei Wong, J. L., Sim, Y. J., Wong, S. S., Mohamed Elhassan, S. A., Tan, S. H., Ling Lim, G. P., Rong Tay, N. W., Annan, N. C., Bhattamisra, S. K., et al. (2019) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2018.10.008 · Cited by 445
Thiazolidinediones and PPARγ agonists: time for a reassessment
Cariou, B., Charbonnel, B., & Staels, B. (2012) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2012.03.001 · Cited by 390
Haw, J. S., Galaviz, K. I., Straus, A. N., Kowalski, A. J., Magee, M. J., Weber, M. B., Wei, J., Narayan, K. M. V., & Ali, M. K. (2017) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2017.6040 · Cited by 354
“62) (Figure 3).(33,44,55-73) Insulin sensitizers (metformin, rosiglitazone, and pioglitazone) achieved an RR reduction of 53% (RR, 0.”
BackgroundStandards of care for type 2 diabetes in China
Weng, J., Ji, L., Jia, W., Lu, J., Zhou, Z., Zou, D., Zhu, D., Chen, L., Chen, L., Guo, L., et al. (2016) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2827 · Cited by 315
DeFronzo, R. A., & Abdul-Ghani, M. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.03.013 · Cited by 317
Pathophysiologic Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes
DeFronzo, R. A., Eldor, R., & Abdul-Ghani, M. (2013) · Diabetes Care · doi:10.2337/dcs13-2011 · Cited by 314
Prediabetes and Cardiovascular Disease
Brannick, B., & Dagogo-Jack, S. (2018) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2017.10.001 · Cited by 293
Therapeutic Use of Metformin in Prediabetes and Diabetes Prevention
Hostalek, U., Gwilt, M., & Hildemann, S. (2015) · Drugs · doi:10.1007/s40265-015-0416-8 · Cited by 278
Diabetes mellitus – Definition, Klassifikation, Diagnose, Screening und Prävention (Update 2019)
Harreiter, J., & Roden, M. (2019) · Wiener klinische Wochenschrift · doi:10.1007/s00508-019-1450-4 · Cited by 253
Prediabetes and Lifestyle Modification: Time to Prevent a Preventable Disease
Tuso, P. (2014) · The Permanente Journal · doi:10.7812/tpp/14-002 · Cited by 252
Preservation of β-Cell Function: The Key to Diabetes Prevention
DeFronzo, R. A., & Abdul-Ghani, M. A. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0246 · Cited by 247
Merlotti, C., Morabito, A., & Pontiroli, A. E. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12270 · Cited by 167
Hopper, I., Billah, B., Skiba, M., & Krum, H. (2011) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1177/1741826711421687 · Cited by 149
“The trials included were the US DPP (Diabetes Prevention Program),(18,19) the Finnish DPS (Diabetes Prevention Study),(20,21) the Da Qing (Da Qing IGT and Diabetes Study),(22,23) the IDPP 1 and 2 (Indian Diabetes Prevention Program 1 and 2), 25 STOP-NIDDM (Acarbose for prevention of type 2 diabetes),(26,27) Kawamori e…”
MethodThe Vasculature in Prediabetes
Wasserman, D. H., Wang, T. J., & Brown, N. J. (2018) · Circulation Research · doi:10.1161/circresaha.118.311912 · Cited by 137
Selph, S., Dana, T., Blazina, I., Bougatsos, C., Patel, H., & Chou, R. (2015) · Annals of Internal Medicine · doi:10.7326/m14-2221 · Cited by 134
“Three trials were rated goodquality (28, 29, 46, 49), and the remainder were fairquality.”
BackgroundJonas, D. E., Crotty, K., Yun, J. D. Y., Middleton, J. C., Feltner, C., Taylor-Phillips, S., Barclay, C., Dotson, A., Baker, C., Balio, C. P., et al. (2021) · JAMA · doi:10.1001/jama.2021.10403 · Cited by 96
Hsueh, W., McLellan, K., Wyne, K., & Villagomez, E. (2014) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s39564 · Cited by 91
“tion Assessment with Ramipril and Rosiglitazone Medication (DREAM trial)(139) and the Canadian Normoglycemia Outcomes Evaluation (CANOE).(140) The DREAM trial recruited 5,269 patients with IFG, IGT, or both, and demonstrated that rosiglitazone was highly effective in reducing the incidence of T2DM by 60% in comparison…”
Metformin and Type 2 Diabetes Prevention
Aroda, V. R., & Ratner, R. E. (2018) · Diabetes Spectrum · doi:10.2337/ds18-0020 · Cited by 70
“P R A C T IC E risk reduction of 26%—providing a number needed to treat of 4 (12).”
BackgroundBell, K., Shaw, J. E., Maple-Brown, L., Ferris, W., Gray, S., Murfet, G., Flavel, R., Maynard, B., Ryrie, H., Pritchard, B., et al. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108188 · Cited by 64
Kramer, C. K., Swaminathan, B., Hanley, A. J., Connelly, P. W., Sermer, M., Zinman, B., & Retnakaran, R. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2341 · Cited by 52
Xiang, A. H., Trigo, E., Martinez, M., Katkhouda, N., Beale, E., Wang, X., Wu, J., Chow, T., Montgomery, C., Nayak, K. S., et al. (2018) · Diabetes Care · doi:10.2337/dc18-1662 · Cited by 37
Yamaoka, K., Nemoto, A., & Tango, T. (2019) · Nutrients · doi:10.3390/nu11061373 · Cited by 32
The Number Needed to Treat: 25 Years of Trials and Tribulations in Clinical Research
Suissa, S. (2015) · Rambam Maimonides Medical Journal · doi:10.5041/rmmj.10218 · Cited by 28
García de la Torre, N., Durán, A., del Valle, L., Fuentes, M., Barca, I., Martín, P., Montañez, C., Perez-Ferre, N., Abad, R., Sanz, F., et al. (2013) · Acta Diabetologica · doi:10.1007/s00592-013-0467-9 · Cited by 24
Metadata
- Authors
- Dungan, J. S.
- Venue
- Yearbook of Obstetrics, Gynecology and Women's Health
- Publisher
- Elsevier BV
- Published
- 2011-01
- Volume
- 2011
- Pages
- 15-16
- ISSN
- 1090-798X (ISSN-L)
- OpenAlex
- W2324523283
- Cited by
- 173
- References
- 22
- FWCI
- 31.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.